Transforming growth factor-β signaling in normal and malignant hematopoiesis

Leukemia

Volumn 17, Issue 9, 2003, Pages 1731-1737

  Kim, S J ^a   Lettirio, J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

CDK inhibitors; Hematopoiesis; Human T cell lymphotropic virus type I (HTLV I); Leukemogenosis; Smad; TGF receptors; Transforming growth factor (TGF )

Indexed keywords

HYBRID PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; ONCOPROTEIN; PROTEIN ETO; PROTEIN EVI 1; PROTEIN P15; PROTEIN P27; SMAD PROTEIN; TAX PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

CELL CYCLE; CELL CYCLE G1 PHASE; DISEASE ASSOCIATION; GENE INACTIVATION; GENE MUTATION; GENE REPRESSION; GENE TARGETING; GENETIC CODE; GENETIC REGULATION; GENETIC TRANSCRIPTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNOREGULATION; IN VIVO STUDY; LEUKEMOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; T CELL LEUKEMIA;

EID: 0141613833     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403069     Document Type: Review

References (106)

1. Massague J. The transforming growth factor-β family. Annu Rev Cell Biol 1990; 6: 597-641.
2. Roberts AB, Sporn MB. In: Sporn MB Roberts AB (eds). Peptide Growth Factors and Their Receptors: Handbook of Experimental Pharmacology, Vol. 95. Heidelberg: Springer-Verlag, 1990, pp 421-472.
3. Glick A, Weinberg W, Wu IH, Quan W, Yuspa SH. Transforming growth factor β suppresses genomic instability independent of a G1 arrest, p53, and Rb. Cancer Res 1996; 56: 3645-3650.
4. Piek E, Heldin C-H, ten Dijke P. Specificity, diversity, and regulation in TGF-β superfamily signaling. FASEB J 1999; 13: 2105-2124.
5. Massague J. How cells read TGF-β signals. Nat Rev Mol Cell Biol 2000; 1: 169-178.
6. Attisano L, Wrana JL. Signal transduction by the TGF-β superfamily. Science 2002; 296: 1646-1647.
7. de Caestecker MP, Piek E, Roberts AB. Role of transforming growth factor-β signaling in cancer. J Natl Cancer Inst 2000; 92: 1388-1402.
8. Hata A. TGF-β signaling and cancer. Exp Cell Res 2001; 264: 111-116.
9. Wotton D, Lo RS, Lee S, Massague J. A Smad transcriptional corepressor. Cell 1999; 97: 29-39.
10. Hayashi H, Abdollah S, Qiu Y, Cai J, Xu YY, Grinnell BW et al. The MAD-related protein Smad7 associates with the TGF-β receptor and functions as an antagonist of TGF-β signaling. Cell 1997; 89: 1165-1173.
11. Yue J, Frey R, Mulder K. Cross-talk between the Smad1 and Ras/MEK signaling pathways for TGF-β. Oncogene 1999; 18: 2033-2037.
12. Sano Y, Harada J, Tashiro S, Gotoh-Mandeville R, Maekawa T, Ishii S. ATF-2 is a common nuclear target of Smad and TAK1 pathways in transforming growth factor-β signaling. J Biol Chem 1999; 274: 8949-8957.
13. Kretzschmar M, Doody J, Timokhina I, Massague J. A mechanism of repression of TGFβ/Smad signaling by oncogenic Ras. Genes Dev 1999; 13: 804-816.
14. Yamaguchi K, Shirakabe K, Shibuya H, Irie K, Oishi I, Ueno N et al. Identification of a member of the MAPKKK family as a potential mediator of TGF-β signal transduction. Science 1995; 270: 2008-2011.
15. Shibuya H, Yamaguchi K, Shirakabe K, Tonegawa A, Gotoh Y, Ueno N et al. TAB1: an activator of the TAK1 MAPKKK in TGF-β signal transduction. Science 1996; 272: 1179-1182.
16. Hartsough MT, Mulder KM. Transforming growth factor β activation of p44mapk in proliferating cultures of epithelial cells. J Biol Chem 1995; 270: 7117-7124.
17. Moriguchi T, Kuroyanagi N, Yamaguchi K, Gotoh Y, Irie K, Kano T et al. A novel kinase cascade mediated by mitogen-activated protein kinase 6 and MKK3. J Biol Chem 1996; 271: 13675-13679.
18. Yoshio T, Nakashima O, Inoshita S, Kuwahara M, Sasaki S, Marumo F. TGF-β-activating kinase-1 inhibits cell cycle and expression of cyclin D1 and A in LLC-PK1 cells. Kidney Int 1999; 56: 1378-1390.
19. Terada Y, Inoshita S, Nakashima O, Kuwahara M, Sasaki S, Marumo F. Regulation of cyclin D1 expression and cell cycle progression by mitogen-activated protein kinase cascade. Kidney Int 1999; 56: 1258-1261.
20. Wang W, Zhou G, Hu M, Yao Z, Tan T. Activation of the hematopoietic progenitor kinase-1 (HPK1)-dependent, stress-activated c-Jun N-terminal kinase (JNK) pathway by transforming growth factor β (TGF-β)-activated kinase (TAK1), a kinase mediator of TGF β signal transduction. J Biol Chem 1997; 272: 22771-22775.
21. Fortunel N, Hatzfeld J, Kisselev S, Monier MN, Ducos K, Cardoso A et al. Release from quiescence of primitive human hematopoietic stem/progenitor cells by blocking their cell-surface TGF-β type II receptor in a short-term in vitro assay. Stem Cells 2000; 18: 102-111.
22. Fortunel NO, Hatzfeld A, Hatzfeld JA. Transforming growth factor-β: pleiotropic role in the regulation of hematopoiesis. Blood 2000; 96: 2022-2036.
23. Keller JR, McNiece IK, Sill KT, Ellingsworth LR, Quesenberry PJ, Sing GK et al. Transforming growth factor β directly regulates primitive murine hematopoietic cell proliferation. Blood 1990; 75: 596-602.
24. Soma T, Yu JM, Dunbar CE. Maintenance of murine long-term repopulating stem cells in ex vivo culture is affected by modulation of transforming growth factor-β but not macrophage inflammatory protein-1α activities. Blood 1996; 87: 4561-4567.
25. Keller JR, Jacobsen SE, Sill KT, Ellingsworth LR, Ruscetti FW. Stimulation of granulopoiesis by transforming growth factor β: synergy with granulocyte/macrophage-colony-stimulating factor. Proc Natl Acad Sci USA 1991; 88: 7190-7194.
26. Jacobsen SE, Ruscetti FW, Dubois CM, Lee J, Boone TC, Keller JR. Transforming growth factor β trans-modulates the expression of colony stimulating factor receptors on murine hematopoietic progenitor cell lines. Blood 1991; 77: 1706-1716.
27. Sugimoto Y, Koji T, Miyoshi S. Modification of expression of stem cell factor by various cytokines. J Cell Physiol 1999; 181: 285-294.
28. Sansilvestri P, Cardoso AA, Batard P, Panterne B, Hatzfeld A, Lim B et al. Early CD34high cells can be separated into KIThigh cells in which transforming growth factor-beta (TGF-β) downmodulates c-kit and KITlow cells in which anti-TGF-β upmodulates c-kit. Blood 1995; 86: 1729-1735.
29. Heinrich MC, Dooley DC, Keeble WW. Transforming growth factor β1 inhibits expression of the gene products for steel factor and its receptor (c-kit). Blood 1995; 85: 1769-1780.
30. Dubois CM, Ruscetti FW, Stankova J, Keller JR. Transforming growth factor-β regulates c-kit message stability and cell-surface protein expression in hematopoietic progenitors. Blood 1994; 83: 3138-3145.
31. Hatzfeld J, Li ML, Brown EL, Sookdeo H, Levesque JP, O'Toole T et al. Release of early human hematopoietic progenitors from quiescence by antisense transforming growth factor beta 1 or Rb oligonucleoticles. J Exp Med 1991; 174: 925-929.
32. Alexandrow MG, Moses HL. Transforming growth factor-β and cell cycle regulation. Cancer Res 1995; 55: 1452-1457.
33. Ewen ME, Sluss HK, Whitehouse LL, Livingston DM. TGF β inhibition of Cdk4 synthesis is linked to cell cycle arrest. Cell 1993; 74: 1009-1020.
34. Geng Y, Weinberg RA. Transforming growth factor β effects on expression of G1 cyclins and cyclin-dependent protein kinases. Proc Natl Acad Sci USA 1993; 90: 10315-10319.
35. Iavarone A, Massague J. Repression of the CDK activator Cdc25A and cellcycle arrest by cytokine TGF-β in cells lacking the CDK inhibitor p15. Nature 1997; 387: 417-422.
36. Hannon GJ, Beach D. p15INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 1994; 371: 257-261.
37. Seoane J, Pouponnot C, Staller P, Schader M, Eilers M, Massagué J. TGF-β influences Myc, Miz and Smad to control the CDK inhibitor p15Ink4b. Nat Cell Biol 2001; 3: 400-408.
38. Sandhu C, Garbe J, Bhattacharya N, Daksis J, Pan CH, Yaswen P et al. Transforming growth factor β stabilizes p15INK4B protein, increases p15INK4B-cdk4 complexes, and inhibits cyclin D1-cdk4 association in human mammary epithelial cells. Mol Cell Biol 1997; 17: 2458-2467.
39. Reynisdottir I, Polyak K, Iavarone A, Massague J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-β. Genes Dev 1995; 9: 1831-1845.
40. Warner BJ, Blain SW, Seoane J, Massague J. Myc downregulation by transforming growth factor β required for activation of the p15(Ink4b) G(1) arrest pathway. Mol Cell Biol 1999; 19: 5913-5922.
41. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF. Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA 1995; 92: 5545-5549.
42. Landesman Y, Bringold F, Milne DD, Meek DW. Modifications of p53 protein and accumulation of p21 and gadd45 mRNA in TCF-β1 growth inhibited cells. Cell Signal 1997; 9: 291-298.
43. Miyazaki M, Ohashi R, Tsuji T, Mihara K, Gohda E, Namba M. Transforming growth factor-β1 stimulates or inhibits cell growth via down- or upregulation of p21/Waf1. Biochem Biophys Res Commun 1998; 246: 873-880.
44. Ducos K, Panterne B, Fortunel N, Hatzfeld A, Monier MN, Hatzfeld J. p21(cip1) mRNA is controlled by endogenous transforming growth factor-β1 in quiescent human hematopoietic stem/progenitor cells. J Cell Physiol 2000; 184: 80-85.
45. Claassen GF, Hann SR. A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor β-induced cell-cycle arrest. Proc Natl Acad Sci USA 2000; 97: 9498-9503.
46. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM et al. p27Kip1 a, cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev 1994; 8: 9-22.
47. Depoortere F, Pirson I, Bartek J, Dumont JE, Roger PP. Transforming growth factor β(1) selectively inhibits the cyclic AMP-dependent proliferation of primary thyroid epithelial cells by preventing the association of cyclin D3-cdk4 with nuclear p27(kip1). Mol Biol Cell 2000; 11: 1061-1076.
48. Pierelli L, Marone M, Bonanno G, Mozzetti S, Rutella S, Morosetti R et al. Modulation of bcl-2 and p27 in human primitive proliferating hematopoietic progenitors by autocrine TGF β1 is a cell cycle-independent effect and influences their hematopoietic potential. Blood 2000; 95: 3001-3009.
49. Dao MA, Hwa J, Nolta JA. Molecular mechanism of transforming growth factor β-mediated cell-cycle modulation in primary human CD34(+) progenitors. Blood 2002; 99: 499-506.
50. Ducos K, Panterne B, Fortunel N, Hatzfeld A, Monier MN, Hatzfeld J. p21(cip1) mRNA is controlled by endogenous transforming growth factor-β1 in quiescent human hematopoietic stem/progenitor cells. J Cell Physiol 2000; 184: 80-85.
51. Dao MA, Taylor N, Nolta JA. Reduction in levels of the cyclin-dependent kinase inhibitor p27(kip-1) coupled with transforming growth factor β neutralization induces cell-cycle entry and increases retroviral transduction of primitive human hematopoietic cells. Proc Natl Acad Sci USA 1998; 95: 13006-13011.
52. Cheng T, Shen H, Rodrigues N, Stier S, Scadden DT. Transforming growth factor-β1 mediates cell-cycle arrest of primitive hematopoietic cells independent of p21Cip1/Waf1 or p27Kip1. Blood 2001; 98: 3643-3649.
53. Batard P, Monier MN, Fortunel N, Ducos K, Sansilvestri-Morel P, Phan T et al. TGF-β1 maintains hematopoietic immaturity by a reversible negative control of cell cycle and induces CD34 antigen up-modulation. J Cell Sci 2000; 113: 383-390.
54. Marone M, Scambia G, Bonanno G, Rutella S, de Ritis D, Guidi F et al. Transforming growth factor-β1 transcriptionally activates CD34 and prevents induced differentiation of TF-1 cells in the absence of any cell-cycle effects. Leukemia 2002; 16: 94-105.
55. Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 1993; 90: 770-774.
56. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M et al. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature 1992; 359: 693-699.
57. Shah AH, Tabayoyong WB, Kimm SY, Kim SJ, Van Parijs L, Lee C. Reconstitution of lethally irradiated adult mice with dominant negative TGF-β type II receptor-transduced bone marrow leads to myeloid expansion and inflammatory disease. J Immunol 2002; 169: 3485-3491.
58. Leveen P, Larsson J, Ehinger M, Cilio CM, Sundler M, Sjostrand LJ et al. Induced disruption of the transforming growth factor beta type II receptor gene in mice causes a lethal inflammatory disorder that is transplantable. Blood 2002; 100: 560-568.
59. Lucas PJ, Kim SJ, Melby SJ, Gress RE. Disruption of T cell homeostasis in mice expressing a T cell-specific dominant negative transforming growth factor β II receptor. J Exp Med 2000; 191: 1187-1196.
60. Gorelik L, Flavell RA. Abrogation of TGF-β signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 2000; 12: 171-181.
61. Piao YF, Ychijo H, Miyagawa K, Ohashi H, Takaku F, Miyazono K. Latent form of transforming growthfactor-β1 acts as a potent growth inhibitor of a human erythroleukemia cell line. Biochem Biophys Res Commun 1990; 167: 27-32.
62. Chen LL, Dean A, Jenkinson T, Mendelson J. Effect of transforming growthfactor-β1 on proliferation and induction of hemoglobin accumulation in K-562 cells. Blood 1989; 74: 2368-2375.
63. Piacibello W, Severino A, Stacchini A, Aglietta M. Differential effects of transforming growthfactor-β1 on the proliferation of human lymphoid and myeloid leukemia cells. Haematologica 1991; 76: 460-466.
64. Schieman WP, Pfeifer WM, Levi E, Kadin ME, Lodish HF. A deletion in the gene for transforming growth factor β type I receptor abolishes growth regulation by transforming growth factor beta in cutaneous T cell lymphoma. Blood 1999; 94: 2854-2861.
65. Knaus PI, Lindemann D, DeCoteau JF, Perlman R, Yankelev H, Hille M et al. A dominant inhibitory mutant of the type II transforming growth factor β receptor in the malignant progression of a cutaneous T cell lymphoma. Mol Cell Biol 1996; 16: 3480-3489.
66. Inman GJ, Allday, MJ. Resistance to TGF-β1 correlates with a reduction of TGF-β type II receptor expression in Burkitt's lymphoma and Epstein-Barr virus-transformed B lymphoblastoid cell lines. J Gen Virol 2000; 81: 1567-1578.
67. Scott S, Kimura T, Ichinohasama R, Bergen S, Magliocco A, Reimer C et al. Microsatellite mutations of transforming growth factor-β receptor type II and caspase-5 occur in human precursor T-cell lymphoblastic lymphomas/leukemias in vivo but are not associated with hMSH2 or hMLH1 promoter methylation. Leukemia Res 2003; 27: 23-34.
68. Molenaar JJ, Gerard B, Chambon-Pautas C, Cave H, Duval M, Vilmer E et al. Microsatellite instability and frameshift mutations in BAX and transforming growth factor-β RII genes are very uncommon in acute lymphoblastic leukemia in vivo but not in cell lines. Blood 1998; 92: 230-233.
69. Rooke HM, Vitas MR, Crosier PS, Crosier KE. The TGF-β type II receptor in chronic myeloid leukemia: analysis of microsatellite regions and gene expression. Leukemia 1999; 13: 535-541.
70. Imai Y, Kurokawa M, Izutsu K, Hangaishi A, Maki K, Ogawa S et al. Mutations of the Smad4 gene in acute myelogeneous leukemia and their functional implications in leukemogenesis. Oncogene 2001; 20: 88-96.
71. Giles RH, Peters DJ, Breuning MH. Conjunction dysfunction: CBP/p300 in human disease. Trends Genet 1998; 14: 178-183.
72. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 1996; 84: 321-330.
73. Yergeau DA, Hetherington CJ, Wang Q, Zhang P, Sharpe AH, Binder M et al. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat Genet 1997; 15: 303-306.
74. Jakubowiak A, Pouponnot C, Berguido F, Frank R, Mao S, Massague J et al. Inhibition of the transforming growth factor β1 signaling pathway by the AML1/ETO leukemia-associated fusion protein. J Biol Chem 2000; 275: 40282-40287.
75. Kitabayashi I, Ida K, Morohoshi F, Yokoyama A, Mitsuhashi N, Shimizu K et al. The AML1-MTG8 leukemic fusion protein forms a complex with a novel member of the MTG8(ETO/CDR) family, MTGR1. Mol Cell Biol 1998; 18: 846-858.
76. Izutsu K, Kurokawa M, Imai Y, Maki K, Mitani K, Hirai H. The corepressor CtBP interacts with Evi-1 to repress transforming growth factor β signaling. Blood 2001; 97: 2815-2822.
77. Ogawa S, Mitani K, Kurokawa M, Matsuo Y, Minowada J, Inazawa J et al. Abnormal expression of Evi-1 gene in human leukemias. Hum Cell 1996; 9: 323-332.
78. Nucifora G. The EVI1 gene in myeloid leukemia. Leukemia 1997; 11: 2022-2031.
79. Kurokawa M, Mitani K, Imai Y, Ogawa S, Yazaki Y, Hirai H. The t(3; 21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-β-mediated growth inhibition of myeloid cells. Blood 1998; 92: 4003-4012.
80. Kurokawa M, Mitani K, Irie K, Matsuyama T, Takahashi T, Chiba S et al. The oncoprotein Evi-1 represses TGF-β signalling by inhibiting Smad3. Nature 1998; 394: 92-96.
81. Yagi K, Furuhashi M, Aoki H, Goto D, Kuwano H, Sugamura K et al. c-myc is a downstream target of the Smad pathway. J Biol Chem 2002; 277: 854-861.
82. Massagué J, Blain SW, Lo RS. TGF-β signaling in growth control, cancer, and heritable disorders. Cell 2000; 103: 295-309.
83. Pietenpol JA, Stein RW, Moran E, Yaciuk P, Schlegel R, Lyons RM et al. TGF-β1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains. Cell 1990; 61: 777-785.
84. Sun Y, Liu X, Eaton EN, Lane WS, Lodish HF, Weinberg RA. Interactioni of the Ski oncoprotein with Smad3 regulates TGF-β signaling. Mol Cell 1999; 4: 499-509.
85. Kretzschmar M, Doody J, Timokhina I, Massagué J. A mechanism of repression of TGF-β/Smad signaling by oncogenic. Ras Gene Dev 1999; 13: 804-816.
86. Sasaki T, Suzuki H, Yagi K, Furuhashi M, Yao R, Susa S et al. Lymphoid enhancer factor 1 makes cells resistant to transforming growth factor β-induced repression of c-myc. Cancer Res 2003; 63: 801-806.
87. Hovanes K, Li TW, Munguia JE, Truong T, Milovanovic T, Lawrence Marsh J et al. β-Catenin-sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer. Nat Genet 2001; 28: 52-57.
88. Komuro H, Valentine MB, Rubnitz JE, Saito M, Raimondi SC, Carroll AJ et al. p27Kip1 deletions in childhood acute lymphoblastic leukemia. Neoplasia 1999; 1: 253-261.
89. Takeuchi C, Takeuchi S, Ikezoe T, Bartram CR, Taguchi H, Koeffler HP, Germline mutation of the p27Kip1 gene in childhood acute lymphoblastic leukemia. Leukemia 2002; 16: 956-958.
90. Morosetti R, Kawamata N, Gomart AF, Miller CW, Hatta Y, Hirama T et al. Alterations of p27Kip1 gene in non-Hodgkin's lymphomas and adult T cell leukemia/lymphoma. Blood 1995; 86: 1924-1930.
91. Kruz U, Ganser A, Koeffler HP. Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene 2002; 21: 3475-3495.
92. Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T cell leukemia: clinical and hematologic features of 16 cases. Blood 1977; 50: 481-492.
93. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980; 77: 7415-7419.
94. Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA 1982; 79: 2031-2035.
95. x and two other phosphoproteins. J Virol 1986; 60: 394-399.
96. Fujii M, Niki T, Mori T, Matsuda T, Matsui M, Nomura N et al. HTLV-1 Tax induces expression of various immediate early serum responsive genes. Oncogene 1991; 6: 1023-1029.
97. tax protein in the human T-cell, line Jurkat. J Virol 1989; 63: 3220-3226.
98. Zhao LJ, Giam CZ. Human T-cell lymphotropic virus type I (HTLV-1) transcriptional activator, Tax, enhances CREB binding to HTLV-I 21-base-pair repeats by protein-protein interaction. Proc Natl Acad Sci USA 1992; 89: 7070-7074.
99. SRF causes the aberrant induction of cellular immediate early genes through CArG boxes. Genes Dev 1992; 6: 2066-2076.
100. Low KG, Dorner LF, Fernando DB, Grossman J, Jeang KT, Comb MJ. Human T-cell leukemia virus type 1 Tax releases cell cycle arrest induced by p16INK4a. J Virol 1997; 71: 1956-1962.
101. Hollsberg P, Ausubel LJ, Hafler DA. Human T cell lymphotropic virus type I-induced T cell activation. Resistance to TGF-β1-induced suppression. J Immunol 1994; 153: 566-573.
102. Mori N, Morishita M, Tsukazaki T, Giam CZ, Kumatori A, Tanaka Y et al. Human T-cell leukemia virus type I oncoprotein Tax represses Smad-dependent transforming growth factor β signaling through interaction with CREB-binding protein/p300. Blood 2001; 97: 2137-2144.
103. Lee DK, Kim BC, Brady JN, Jeang KT, Kim SJ. Human T-cell lymphotropic virus type 1 tax inhibits transforming growth factor-beta signaling by blocking the association of Smad proteins with Smad-binding element. J Biol Chem 2002; 277: 33766-33775.
104. Arnulf B, Villemain A, Nicot C, Mordelet E, Charneau P, Kersual J et al. Human T-cell lymphotropic virus oncoprotein Tax represses TGF-β1 signaling in human T cells via c-jun activation: a potential mechanism of HTLV-I leukemogenesis. Blood 2002; 100: 4129-4138.
105. Kim SJ, Kehrl JH, Burton J, Tendler CL, Jeang KT, Danielpour D et al. Transactivation of the transforming growth factor β1 (TGF-β1) gene by human T lymphotropic virus type 1 tax: a potential mechanism for the increased production of TGF-β1 in adult T cell leukemia. J Exp Med 1990; 172: 121-129.
106. Kim SJ, Winokur TS, Lee HD, Danielpour D, Kim KY, Geiser AG et al. Overexpression of transforming growth factor-β in transgenic mice carrying the human T-cell lymphotropic virus type I tax gene. Mol Cell Biol 1991; 11: 5222-5228.